Lexicon Pharmaceuticals Valuation
| LXRX Stock | USD 0.80 0.02 2.44% |
Today, the firm appears to be undervalued. Lexicon Pharmaceuticals secures a last-minute Real Value of $1.98 per share. The latest price of the firm is $0.8. Our model forecasts the value of Lexicon Pharmaceuticals from analyzing the firm fundamentals such as Return On Equity of -1.36, shares outstanding of 361.49 M, and Operating Margin of (36.40) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Lexicon Pharmaceuticals' valuation include:
Price Book 1.6299 | Enterprise Value 133.8 M | Enterprise Value Ebitda (2.58) | Price Sales 55.6445 | Enterprise Value Revenue 25.5866 |
Undervalued
Today
Please note that Lexicon Pharmaceuticals' price fluctuation is dangerous at this time. Calculation of the real value of Lexicon Pharmaceuticals is based on 3 months time horizon. Increasing Lexicon Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Lexicon Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Lexicon Stock. However, Lexicon Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.8 | Real 1.98 | Target 5.55 | Hype 0.72 | Naive 1.07 |
The intrinsic value of Lexicon Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Lexicon Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Lexicon Pharmaceuticals helps investors to forecast how Lexicon stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Lexicon Pharmaceuticals more accurately as focusing exclusively on Lexicon Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Lexicon Pharmaceuticals' intrinsic value based on its ongoing forecasts of Lexicon Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Lexicon Pharmaceuticals' closest peers.
Lexicon Pharmaceuticals Cash |
|
Lexicon Valuation Trend
Analysing the historical paterns of Lexicon Pharmaceuticals' enterprise value and its market capitalization is a good way to estimate and gauge the value of Lexicon Pharmaceuticals over time and is usually enough for investors to make rational market timing decisions.
Lexicon Pharmaceuticals Total Value Analysis
Lexicon Pharmaceuticals is now projected to have valuation of 133.79 M with market capitalization of 290.96 M, debt of 106.06 M, and cash on hands of 61.97 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Lexicon Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
133.79 M | 290.96 M | 106.06 M | 61.97 M |
Lexicon Pharmaceuticals Investor Information
About 82.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.63. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Lexicon Pharmaceuticals recorded a loss per share of 0.74. The entity had not issued any dividends in recent years. The firm had 1:7 split on the 21st of May 2015. Based on the key indicators related to Lexicon Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Lexicon Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.Lexicon Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Lexicon Pharmaceuticals has an asset utilization ratio of 0.52 percent. This suggests that the Company is making $0.005248 for each dollar of assets. An increasing asset utilization means that Lexicon Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Lexicon Pharmaceuticals Ownership Allocation
Lexicon Pharmaceuticals maintains a total of 361.49 Million outstanding shares. The majority of Lexicon Pharmaceuticals outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Lexicon Pharmaceuticals to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Lexicon Pharmaceuticals. Please pay attention to any change in the institutional holdings of Lexicon Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Lexicon Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 1.2 M. Net Loss for the year was (177.12 M) with loss before overhead, payroll, taxes, and interest of (52.68 M).About Lexicon Pharmaceuticals Valuation
Our relative valuation model uses a comparative analysis of Lexicon Pharmaceuticals. We calculate exposure to Lexicon Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Lexicon Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 1.1 M | 1.1 M | |
| Pretax Profit Margin | (147.11) | (154.46) | |
| Operating Profit Margin | (142.65) | (135.52) | |
| Net Loss | (147.11) | (139.75) | |
| Gross Profit Margin | 0.93 | 0.98 |
Lexicon Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 221.1 M | |
| Quarterly Earnings Growth Y O Y | -0.634 |
Lexicon Pharmaceuticals Current Valuation Indicators
Valuation refers to the process of determining the present value of Lexicon Pharmaceuticals and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Lexicon we look at many different elements of the entity such as Lexicon's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Lexicon Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Lexicon Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Lexicon Pharmaceuticals' worth.Additional Tools for Lexicon Stock Analysis
When running Lexicon Pharmaceuticals' price analysis, check to measure Lexicon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceuticals is operating at the current time. Most of Lexicon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexicon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lexicon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.